전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-3 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved2,047 programs
AntibodyLimited DatastaleAbbViePhase 1

Lemzoparlimab (Lemzoparlimab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase1#monoclonal-antibody#AbbVie
Trials 1Status Discontinued
AntibodyLimited DatastaleRochePhase 3

Lenalidomide and rituximab (R2, Lenalidomide and rituximab, Lenalidomide and rituximab (R2) in 28-day cycles for up to 12 cycles.)

Follicular Lymphoma (FL) · Follicular Lymphoma (FL)

#FollicularLymphomaFL#Antibody#Phase3#monoclonal-antibody#Roche
Trials 1Status Recruiting
CGTLimited DatastaleIovance Biotherapeutics, Inc.Phase 3

pembrolizumab (Keytruda, Lifileucel plus Pembrolizumab)

Metastatic Melanoma; Unresectable Melanoma · Metastatic Melanoma

#MetastaticMelanoma#Antibody#Phase3#monoclonal-antibody#UnresectableMelanoma+1
Trials 1Status Recruiting
AntibodyLimited DatastaleGroupe Oncologie Radiotherapie …Phase 3

Ligufalimab (Ligufalimab)

Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) · Squamous Cell Carcinoma Head and Neck Ca

#SquamousCellCarcinomaHeadandNeck#Antibody#Phase3#monoclonal-antibody#Groupe
Trials 1Status Recruiting
AntibodyLimited DatastaleAbbViePhase 3

Livmoniplimab (Livmoniplimab)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase3#monoclonal-antibody#AbbVie
Trials 1Status Recruiting
AntibodyLimited DatastaleADC TherapeuticsPhase 1

durvalumab (Imfinzi, Loncastuximab Tesirine and Durvalumab)

Diffuse Large B-Cell Lymphoma; Mantle Cell Lymphoma · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#Antibody#Phase1#monoclonal-antibody#MantleCellLymphoma+1
Trials 1Status Discontinued
AntibodyLimited DatastaleBayerPhase 1

BAY1129980 (Lupartumab Amadotin, Lupartumab Amadotin (BAY1129980))

Neoplasms · Neoplasms

#Neoplasms#Antibody#Phase1#monoclonal-antibody#Bayer
Trials 1Status Discontinued
AntibodyLimited DatastaleBond Avillion 2 Development LPPhase 2

Sonelokimab (M1095, M1095 (Sonelokimab))

Psoriasis · Psoriasis

#Psoriasis#Antibody#Phase2#monoclonal-antibody#Bond
Trials 1Status Active
AntibodyLimited DatastaleEvangelos J. Giamarellos-Bourbo…Phase 2

MABp1 (MABp1)

Hidradenitis Suppurativa · Hidradenitis Suppurativa

#HidradenitisSuppurativa#Antibody#Phase2#monoclonal-antibody#Evangelos
Trials 1Status Active
AntibodyLimited DatastaleIRCCS National Neurological Ins…Preclinical

MAbs (MAbs)

Migraine Disorders; Chronic Migraine · Migraine Disorders

#MigraineDisorders#Antibody#Preclinical#monoclonal-antibody#ChronicMigraine+1
Trials 1Status Recruiting
CGTLimited DatastaleMiltenyi Biomedicine GmbHPhase 2

MB-CART20.1 (MB-CART20.1)

Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 3

Bevacizumab Biosimilar Drug (MB02, MB02 (Bevacizumab Biosimilar Drug))

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase3#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastalemAbxience Research S.L.Phase 1

Bevacizumab Biosimilar (MB02, MB02 (Bevacizumab Biosimilar))

Healthy Volunteers · Healthy Volunteers

#HealthyVolunteers#Antibody#Phase1#monoclonal-antibody#mAbxience
Trials 1Status Active
AntibodyLimited DatastaleMerus B.V.Phase 2

pembrolizumab (Keytruda, MCLA-158 + Pembrolizumab)

Advanced/Metastatic Solid Tumors; Colorectal Cancer · Advanced/Metastatic Solid Tumors

#AdvancedMetastaticSolidTumors#Antibody#Phase2#monoclonal-antibody#Advanced+3
Trials 1Status Recruiting
CGTLimited DatastaleTechnische Universität DresdenPhase 1

BCMA directed CAR T-cells (MDC-CAR-BCMA001, MDC-CAR-BCMA001 (BCMA directed CAR T-cells))

Neoplasms; Relapsed Diffuse Large B-cell Lymphoma (DLBCL) · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleMedImmune LLCPhase 2

durvalumab (Imfinzi, MEDI6469 Plus Durvalumab)

Advanced Solid Tumors; Aggressive B-cell Lymphomas · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase2#monoclonal-antibody#AggressiveB-cellLymphomas+1
Trials 1Status Discontinued
AntibodyLimited DatastaleMedImmune LLCPhase 2

MEDI6469 Plus Tremelimumab (MEDI6469 Plus Tremelimumab)

Advanced Solid Tumors; Aggressive B-cell Lymphomas · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase2#monoclonal-antibody#AggressiveB-cellLymphomas+1
Trials 1Status Discontinued
AntibodyLimited DatastaleMedImmune LLCPhase 2

MEDI6469 plus Rituximab (MEDI6469 plus Rituximab)

Advanced Solid Tumors; Aggressive B-cell Lymphomas · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase2#monoclonal-antibody#AggressiveB-cellLymphomas+1
Trials 1Status Discontinued
AntibodyLimited DatastaleMedivirPhase 2

pembrolizumab (Keytruda, MIV-818, MIV-818 (fostroxacitabine bralpamide) + pembrolizumab, fostroxacitabine bralpamide)

Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#IntrahepaticCholangiocarcinoma+1
Trials 1Status Active
CGTLimited DatastaleUniversity of PennsylvaniaPhase 1

MOv19-BBz CAR T cells (MOv19-BBz CAR T cells)

Metastatic Non Small Cell Lung Cancer; Recurrent Lung Non-Small Cell Carcinoma · Metastatic Non Small Cell Lung Cancer

#MetastaticNonSmallCellLungCancer#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting

72 / 103 pages

← PreviousNext →